NeOnc Technologies Holdings is trading at $3.44 (+5.20%) after announcing plans for an approximately 500-patient brain-cancer trial.
- On October 26, the company described a proposed trial spanning 30 hospitals in three countries during a television appearance.
- Those figures are planned scope, not completed enrollment; this was the clearest company-specific catalyst identified for the morning gain.
- Broader indices were modestly higher, but none reached the 0.5% threshold for emphasizing market-wide sentiment.